Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.
DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for a staggering $2.1 billion. The news sent Avadel's stock price soaring in premarket trading, reflecting a significant premium offered to its investors.
Analysts' ratings for Alkermes (NASDAQ: ALKS) over the last quarter vary from bullish to bearish, as provided by 9 analysts. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
ALKERMES PLC (ALKS) is a strong value stock with low P/E ratios, high profitability, and a debt-free balance sheet, making it an attractive pick for long-term investors.
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.
ALKERMES PLC (NASDAQ:ALKS) shows strong profitability and financial health while trading at a discount to peers, making it a potential value opportunity in biopharma.
